Home › Compare › IXSBF vs JNJ

IXSBF vs JNJ: Dividend Comparison 2026

IXSBF yields 2000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IXSBF wins by $4.879226400974806e+39M in total portfolio value
10 years
IXSBF
IXSBF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full IXSBF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — IXSBF vs JNJ

📍 IXSBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIXSBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IXSBF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IXSBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IXSBF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, IXSBF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IXSBF + JNJ for your $10,000?

IXSBF: 50%JNJ: 50%
100% JNJ50/50100% IXSBF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

IXSBF
No analyst data
Altman Z
-21.6
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IXSBF buys
0
JNJ buys
0
No recent congressional trades found for IXSBF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIXSBFJNJ
Forward yield2000000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.879226400974806e+39M$20.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.879195005460081e+39M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IXSBF vs JNJ ($10,000, DRIP)

YearIXSBF PortfolioIXSBF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,676$355.77+$200.00M → IXSBF
2$3,738,731,768,458$3,738,517,757,009.35$11,407$389.39+$3738731.76M → IXSBF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,198$426.53+$65315062866.92M → IXSBF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,056$467.62+$1066400830062625.00M → IXSBF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$13,987$513.12+$16272182796453826560.00M → IXSBF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$14,998$563.56+$2.3205424011366188e+23M → IXSBF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$16,098$619.52+$3.0927990661046884e+27M → IXSBF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,295$681.69+$3.8524105697352695e+31M → IXSBF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$18,599$750.82+$4.484688260147987e+35M → IXSBF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.879226400974806e+39M → IXSBF

IXSBF vs JNJ: Complete Analysis 2026

IXSBF — Stock

InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.

Full IXSBF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this IXSBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IXSBF vs SCHDIXSBF vs JEPIIXSBF vs OIXSBF vs KOIXSBF vs MAINIXSBF vs ABBVIXSBF vs MRKIXSBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.